Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lenalidomide, quantity: 20 mg - capsule - excipient ingredients: lactose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; shellac glaze-45% (20% esterified) in ethanol - multiple myeloma (mm) lenalidomide is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lenalidomide, quantity: 15 mg - capsule - excipient ingredients: lactose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; shellac glaze-45% (20% esterified) in ethanol - multiple myeloma (mm) lenalidomide is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lenalidomide, quantity: 10 mg - capsule - excipient ingredients: lactose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; shellac glaze-45% (20% esterified) in ethanol - multiple myeloma (mm) lenalidomide is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lenalidomide, quantity: 5 mg - capsule - excipient ingredients: lactose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - multiple myeloma (mm) lenalidomide is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. lenalidomide is indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.,myelodysplastic syndromes (mds) lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - deferasirox, quantity: 360 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; poloxamer; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 8000; purified talc; iron oxide red - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. [invented name] is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. [invented name] is also indicated for the treatment of chronic iron overload in patients with non-transfusiondependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; poloxamer; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 8000; purified talc; iron oxide red - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. [invented name] is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. [invented name] is also indicated for the treatment of chronic iron overload in patients with non-transfusiondependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; poloxamer; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 8000; purified talc; iron oxide red - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. [invented name] is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. [invented name] is also indicated for the treatment of chronic iron overload in patients with non-transfusiondependent thalassemia syndromes aged 10 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - simvastatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - simvastatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - simvastatin -